Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers

(2015) Ryan B. Corcoran et al.   Oncotarget

Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma

(2012) Sapna P. Patel et al.   CANCER

Targeting NRAS in Melanoma

(2012) Fergal C. Kelleher et al.   CANCER JOURNAL

Vemurafenib

(2012) Anant Sharma et al.   DRUGS

Sorafenib in melanoma

(2012) Joanna Mangana et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The role of BRAF V600 mutation in melanoma

(2012) Paolo A Ascierto et al.   Journal of Translational Medicine

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

(2012) J. G. Greger et al.   MOLECULAR CANCER THERAPEUTICS

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies

(2012) Lise Willems et al.   Current Oncology Reports

Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition

(2011) K. P. Hoeflich et al.   CANCER RESEARCH

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

(2011) J. M. Kirkwood et al.   CLINICAL CANCER RESEARCH

New drugs in melanoma: It’s a whole new world

(2011) Alexander M.M. Eggermont et al.   EUROPEAN JOURNAL OF CANCER

PLX4032 and melanoma: resistance, expectations and uncertainty

(2011) Dimitrios H Roukos   Expert Review of Anticancer Therapy

The cost of drug development: A systematic review

(2011) Steve Morgan et al.   HEALTH POLICY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of KIT expression and KIT exon 11 mutations in canine oral malignant melanomas

(2011) A. Murakami et al.   Veterinary and Comparative Oncology

C-kit Expression in Canine Mucosal Melanomas

(2011) S. J. Newman et al.   VETERINARY PATHOLOGY

PLX4032: does it keep its promise for metastatic melanoma treatment?

(2010) Elisabeth Livingstone et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition

(2009) O. K. Mirzoeva et al.   CANCER RESEARCH

Mouse models for melanoma: a personal perspective

(2009) Jürgen C. Becker et al.   EXPERIMENTAL DERMATOLOGY

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

(2009) M. L. Sos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

(2008) K. S.M. Smalley et al.   MOLECULAR CANCER THERAPEUTICS

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA